Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects.

Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations.

An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 ...

Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year ...